MDPI and ACS Style
Wind, S.S.; Jansen, M.A.A.; Rijsbergen, M.; van Esdonk, M.J.; Ziagkos, D.; Cheng, W.C.; Niemeyer-van der Kolk, T.; Korsten, J.; Gruszka, A.; Schmitz-Rohmer, D.;
et al. Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510. Cancers 2023, 15, 1485.
https://doi.org/10.3390/cancers15051485
AMA Style
Wind SS, Jansen MAA, Rijsbergen M, van Esdonk MJ, Ziagkos D, Cheng WC, Niemeyer-van der Kolk T, Korsten J, Gruszka A, Schmitz-Rohmer D,
et al. Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510. Cancers. 2023; 15(5):1485.
https://doi.org/10.3390/cancers15051485
Chicago/Turabian Style
Wind, Selinde S., Manon A. A. Jansen, Melanie Rijsbergen, Michiel J. van Esdonk, Dimitrios Ziagkos, Wing C. Cheng, Tessa Niemeyer-van der Kolk, John Korsten, Agnieszka Gruszka, Debora Schmitz-Rohmer,
and et al. 2023. "Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510" Cancers 15, no. 5: 1485.
https://doi.org/10.3390/cancers15051485